Decoding the satiety signal

Research reveals how leptin and its receptor work together to regulate hunger signals

The protein hormone leptin signals our brains that we are full and can stop eating. To send that signal, leptin has to bind to a receptor on the cells that need to receive the message. Researchers at the VIB-UGent Center for Inflammation Research, collaborating with colleagues at Osnabruck University (Germany) and the Belgian biotechnology company PUXANO, have now revealed how leptin and its receptor work together. Their arresting research results appear in the leading scientific journal Nature Structural & Molecular Biology and may spark new approaches in treating obesity, a major metabolic condition worldwide.

The satiety hormone

In 1994, the American scientist Jeffrey Friedman discovered the hormone leptin. He wanted to understand why some lab mice strains could not stop eating. Eventually, he zeroed in on leptin, now also known as the satiety hormone, which regulates body weight and other biological processes involved in immunity, fertility, and cancer, for example.

Leptin is made by white fat cells and the gastric mucosa. When the leptin levels are high, our brains receive the signal that our energy stores are sufficient and we don't need to eat. We feel full, in other words. That 'I'm full' signal is passed along by leptin when it binds to the leptin receptor (LEP-R) on the surface of brain cells.

Dr. Kenneth Verstraete, who led the research with prof. Savvas Savvides (VIB-UGent Center for Inflammation research): "The receptor for Leptin has six different forms with varying activity levels. The longest form of the receptor can send signals to the brain and is linked to energy balance and food intake. The leptin-receptor assembly took us completely by surprise! It is constructed by three leptin molecules connecting three receptor molecules, which offers important new insights to understand how leptin functions."

Visualizing the leptin-LEP-R receptor complex

The researchers used X-ray crystallography and Cryo-Electron Microscopy to determine the 3D-structure of the leptin- LEP-R assemblies to near-atomic resolution and single-molecule tracking to confirm such complexes on living cells. Such an innovative combination of methods was critical to the project's success. The researchers found that leptin induces a unique type of receptor assembly and undergoes structural changes that activate its binding to LEP-R.

Dr. Alexandra Tsirigotaki, first author of the study: "We know that specific mutations in leptin and the leptin receptor are associated with severe obesity. Our findings now explain such clinically important mutations and will be an important resource for the large community studying leptin signaling in basic and clinical science."

This new understanding of how leptin interacts with its receptors at the cell surface has important implications for understanding how the hormone works in the body.

Prof. Savvas Savvides: "Collectively, our work will help to consolidate two decades of research on the role of leptin in physiology and disease and will catalyze the development of treatments for leptin dysfunction and the creation of new variants of leptin with improved properties."

Publication

Mechanism of receptor assembly via the pleiotropic adipokine Leptin. Tsirigotaki et al. Nature Structural & Molecular Biology, 2023.


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be